{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:40:02Z","timestamp":1745642402780,"version":"3.40.4"},"reference-count":19,"publisher":"Japanese Urological Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2024,4,20]]},"DOI":"10.5980\/jpnjurol.115.64","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T22:07:17Z","timestamp":1745100437000},"page":"64-71","source":"Crossref","is-referenced-by-count":0,"title":["EARLY OUTCOMES OF REFRACTORY OVERACTIVE BLADDER TREATED WITH BOTULINUM TOXIN IN A FEMALE UROLOGY CLINIC","\u5973\u6027\u6ccc\u5c3f\u5668\u79d1\u306b\u304a\u3051\u308b\u5916\u6765\u30dc\u30c4\u30ea\u30cc\u30b9\u7642\u6cd5\u306e\u521d\u671f\u7d4c\u9a13"],"prefix":"10.5980","volume":"115","author":[{"given":"Kumiko","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Female Urology, Meitetsu Hospital"},{"name":"Department of Female Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aika","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sai","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hirabayashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Female Urology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemori","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Urology, Meitetsu Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Narushima","sequence":"additional","affiliation":[{"name":"Department of Female Urology, Meitetsu Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4001","reference":[{"key":"1","unstructured":"2) \u65e5\u672c\u6392\u5c3f\u6a5f\u80fd\u5b66\u4f1a\u904e\u6d3b\u52d5\u8180\u80f1\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u4f5c\u6210\u59d4\u54e1\u4f1a\u7de8: \u904e\u6d3b\u52d5\u8180\u80f1\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\uff3b\u7b2c2\u7248\uff3d, \u30ea\u30c3\u30c1\u30d2\u30eb\u30e1\u30c7\u30a3\u30ab\u30eb, \u6771\u4eac, 2015."},{"key":"2","unstructured":"3) \u65e5\u672c\u6392\u5c3f\u6a5f\u80fd\u5b66\u4f1a, \u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a\u7de8: \u904e\u6d3b\u52d5\u8180\u80f1\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\uff3b\u7b2c3\u7248\uff3d, \u30ea\u30c3\u30c1\u30d2\u30eb\u30e1\u30c7\u30a3\u30ab\u30eb, \u6771\u4eac, 2022."},{"key":"3","unstructured":"4) \u65e5\u672c\u6392\u5c3f\u6a5f\u80fd\u5b66\u4f1a\u30fb\u65e5\u672c\u6ccc\u5c3f\u5668\u79d1\u5b66\u4f1a \u904e\u6d3b\u52d5\u8180\u80f1\u30fb\u795e\u7d4c\u56e0\u6027\u8180\u80f1\u306b\u5bfe\u3059\u308b\u30dc\u30c4\u30ea\u30cc\u30b9\u7642\u6cd5\u9069\u6b63\u4f7f\u7528\u6307\u91dd\u4f5c\u6210\u59d4\u54e1\u4f1a: \u904e\u6d3b\u52d5\u8180\u80f1\u30fb\u795e\u7d4c\u56e0\u6027\u8180\u80f1\u306b\u5bfe\u3059\u308b\u30dc\u30c4\u30ea\u30cc\u30b9\u7642\u6cd5\u9069\u6b63\u4f7f\u7528\u6307\u91dd. 2021.3.14. http:\/\/japanese-continence-society.kenkyuukai.jp\/special\/index.asp"},{"key":"4","doi-asserted-by":"crossref","unstructured":"5) Giannantoni A, Carbone A, Carone R, Cervigni M, Del Popolo G, Agr\u00f2 EF, Giocoli Nacci G, Palleschi G, Salvatore S, Spinelli M and Tubaro A: Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement. World J Urol., 35, 299-306, 2017.","DOI":"10.1007\/s00345-016-1847-x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"6) Yokoyama O, Honda M, Yamanishi T, Sekiguchi Y, Fujii K, Nakayama T and Mogi T: OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis). Int J Urol., 27, 227-234, 2020.","DOI":"10.1111\/iju.14176"},{"key":"6","doi-asserted-by":"crossref","unstructured":"7) Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X and Haag-Molkenteller C; EMBARK Study Group: OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol., 189, 2186-2193, 2013.","DOI":"10.1016\/j.juro.2012.12.022"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8) Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J and Haag-Molkenteller C: OnabotulinumtoxinA 100U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol., 64, 249-256, 2013.","DOI":"10.1016\/j.eururo.2013.04.001"},{"key":"8","doi-asserted-by":"publisher","unstructured":"9) Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, Yamanishi T, Yamaguchi O, Takeda M and Nishizawa O: Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology, 68, 318-323, 2006.","DOI":"10.1016\/j.urology.2006.02.042"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10) \u672c\u9593\u4e4b\u592b, \u585a\u672c\u6cf0\u53f8, \u5b89\u7530\u8015\u4f5c, \u5927\u5712\u8aa0\u4e00\u90ce, \u5409\u7530\u6b63\u8cb4, \u9032\u58eb\u6075\u7f8e: International Prostate Symptom Score\u3068BPH Impact Index\u306e\u65e5\u672c\u8a9e\u8a33\u306e\u8a00\u8a9e\u7684\u59a5\u5f53\u6027\u306b\u95a2\u3059\u308b\u7814\u7a76. \u65e5\u6ccc\u5c3f\u4f1a\u8a8c, 93, 669-680, 2002.","DOI":"10.5980\/jpnjurol1989.93.669"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11) Yalcin I and Bump RC: Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol., 189, 98-101, 2003.","DOI":"10.1067\/mob.2003.379"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12) Kanada Y: Investigation of the freely available easy-to-use software  'EZR' for medical statistics. Bone Marrow Transplant., 48, 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"12","unstructured":"13) \u672c\u7530\u6b63\u53f2, \u6b66\u4e2d \u7be4: \u3010\u6ccc\u5c3f\u5668\u5185\u8996\u93e1\u6700\u65b0\u624b\u8853\u3011\u5c3f\u7ba1\u30fb\u8180\u80f1\u306e\u624b\u8853 \u30dc\u30c4\u30ea\u30cc\u30b9\u6bd2\u7d20\u8180\u80f1\u58c1\u5185\u6ce8\u5165\u7642\u6cd5. \u81e8\u6ccc, 77, 118-122, 2023."},{"key":"13","unstructured":"14) \u65e5\u672c\u6392\u5c3f\u6a5f\u80fd\u5b66\u4f1a\u5973\u6027\u4e0b\u90e8\u5c3f\u8def\u75c7\u72b6\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u4f5c\u6210\u59d4\u54e1\u4f1a\u7de8: \u5973\u6027\u4e0b\u90e8\u5c3f\u8def\u75c7\u72b6\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\uff3b\u7b2c2\u7248\uff3d, \u30ea\u30c3\u30c1\u30d2\u30eb\u30e1\u30c7\u30a3\u30ab\u30eb, \u6771\u4eac, 2019."},{"key":"14","doi-asserted-by":"crossref","unstructured":"15) Hsiao SM, Lin HH and Kuo HC: Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome. PLoS One, 11, e0147137, 2016.","DOI":"10.1371\/journal.pone.0147137"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16) Yokoyama O, Honda M, Yamanishi T, Sekiguchi Y, Fujii K, Kinoshita K, Nakayama T, Ueno A and Mogi T: Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial. Int Urol Nephrol., 53, 2243-2250, 2021.","DOI":"10.1007\/s11255-021-02962-z"},{"key":"16","unstructured":"17) \u52a0\u85e4\u4e45\u7f8e\u5b50: \u5c0f\u3055\u306a\u5de5\u592b \u904e\u6d3b\u52d5\u8180\u80f1\u30dc\u30c4\u30ea\u30cc\u30b9\u7642\u6cd5\u306e\u5c0e\u5165 \u6b21\u4e9c\u5869\u7d20\u9178\u30ca\u30c8\u30ea\u30a6\u30e0\u6eb6\u6db2\u306b\u3088\u308b\u5931\u6d3b\u3068\u5ec3\u68c4\u306e\u7c21\u4fbf\u5316. \u81e8\u6ccc, 76, 756-757, 2022."},{"key":"17","doi-asserted-by":"crossref","unstructured":"18) Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, De Ridder D, Jenkins B, Magyar A and Chapple C; 191622-096 Investigators: Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol., 196, 791-800, 2016.","DOI":"10.1016\/j.juro.2016.03.146"},{"key":"18","doi-asserted-by":"crossref","unstructured":"19) Elbaset MA, Taha DE, El-Hefnawy AS, Zahran MH and Shokeir AA: Assessment of Anticholinergic Use After Fading of BTX-A Effects in Refractory Idiopathic Overactive Bladder: A Prospective Blinded Randomized Trial. Int Neurourol J., 23, 240-248, 2019.","DOI":"10.5213\/inj.1938098.049"},{"key":"19","doi-asserted-by":"crossref","unstructured":"20) Moskowitz D, Adelstein SA, Lucioni A, Lee UJ and Kobashi KC: Use of Third Line Therapy for Overactive Bladder in a Practice with Multiple Subspecialty Providers-Are We Doing Enough? J Urol., 199, 779-784, 2018.","DOI":"10.1016\/j.juro.2017.09.102"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/115\/2\/115_64\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:05:25Z","timestamp":1745640325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/115\/2\/115_64\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.115.64","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"type":"print","value":"0021-5287"},{"type":"electronic","value":"1884-7110"}],"subject":[],"published":{"date-parts":[[2024,4,20]]}}}